Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction
- Editor
- Mar 18
- 1 min read
Whats Happening:
Cyrano Therapeutics and Resyca have entered into an exclusive licensing agreement for Resyca's soft mist nasal spray technology to treat chemosensory disorders, including post-viral smell loss. This partnership aims to enhance the efficacy of Cyrano's lead therapy, CYR-064, by optimizing drug delivery to the olfactory region.
Key Moves:
Exclusive licensing agreement between Cyrano Therapeutics and Resyca for soft mist nasal spray technology
Technology designed to enhance drug deposition in the olfactory region for treating smell loss
Cyrano's Phase 2 FLAVOR clinical study for CYR-064 utilizing Resyca's technology nearing completion
By The Numbers:
Top-line data for CYR-064 Phase 2 FLAVOR study expected in second half of 2025
Resyca's technology integrated into Ursatec's spray pump technology
No FDA-approved therapy currently exists for the treatment of smell loss
Key Quotes:
"This agreement with Resyca enables us to enhance the efficacy of our treatment for patients experiencing chemosensory dysfunction by delivering our proprietary formulation through their advanced soft mist technology," - Rick Geoffrion, CEO of Cyrano Therapeutics
"Our patented nasal soft mist technology enables advanced drug delivery for both biologics and small molecules. Partnering with Cyrano Therapeutics aligns with our mission to drive innovation in drug delivery solutions." - Remko Beimers, CEO of Resyca
Bottom Line:
The partnership between Cyrano Therapeutics and Resyca represents a significant step forward in developing an innovative treatment for smell loss, a condition with no current FDA-approved therapy. By combining Cyrano's CYR-064 with Resyca's soft mist nasal spray technology, this collaboration aims to improve drug delivery and efficacy for patients suffering from chemosensory disorders.
Comments